SIM Tracer

Anchoring principle: Position B’s objections are tied to specific record gaps (missing microglial assay, Kp,uu 0.22 with P-gp efflux) rather than preference. Resolve-support-to-stated-basis principle: Position A’s precedents (dapansutrile/PC7B071, VENT-02/PCF4B44, ALS whole-blood/PDEB9AF) share mechanism and potency class but all break on the CNS-relevant dimension that the candidate lacks; their common-scale basis does not support sufficiency without central engagement data. Give-disqualifying-objection-weight principle: the missing microglial assay is a material gap that directly undermines the bridge from peripheral potency to CNS pharmacology. Separate-verified-from-reported principle: the 17.7 nM whole-blood IC50 and Kp,uu 0.22 are verified, but the peripheral-to-central efficacy bridge and the sufficiency of peripheral-only suppression are reported/speculative. Treat-convergence-as-unearned principle: the field-debate precedent (P340E7B) is explicitly contested and therefore cannot substantiate that peripheral-only engagement is sufficient. Because the claim of sufficiency requires accepting an unresolved hypothesis against a field precedent pattern that consistently includes CNS-relevant data for AD advancement, the evidence favors B. What would change the answer: a microglial NLRP3 IC50 showing engagement at predicted unbound brain concentrations, or CSF/brain PKPD data confirming central target engagement.

The claim that target engagement evidence is sufficient to advance to in-vivo AD-efficacy studies at the commit-to-animal gate is not supported on the record. First, the potency anchor is decision-fragile: a geometric mean derived from n=2 retained replicates after excluding two of four runs for quality failures provides inadequate statistical foundation for a load-bearing commitment to efficacy studies. Second, for an Alzheimer’s disease indication—a CNS disease—the record contains zero verified evidence of central NLRP3 engagement. The candidate’s brain penetration rests solely on a reported Kp,uu of ~0.22 and design intent, with no reported microglial assay, CSF exposure, or CNS biomarker modulation. Position A cites mechanism-class precedents (dapansutrile, VEN-02XX, NT-0796, VENT-02, usnoflast) that demonstrated AD-model rescue or clinical CSF biomarker modulation, but in every case the comparability assessment acknowledges the precedent possessed verified CNS engagement that this candidate lacks. Shared mechanism and brain-penetrant design intent do not transfer sufficiency when the specific evidentiary gap is central engagement. Third, the field-level precedent on peripheral-versus-central NLRP3 sufficiency (precedent_p340e7b) records an unresolved debate, which means peripheral whole-blood potency cannot be presumed adequate for AD efficacy; it merely does not preclude it, which is a weaker standard than sufficiency. The strongest open objection is the complete absence of any CNS target engagement data for this candidate; if a microglial potency assay, rodent CSF exposure measurement, or CNS biomarker study were added, the resolution could shift toward sufficiency.

The claim under review is whether the target engagement evidence is sufficient to justify in-vivo AD-efficacy experiments at the commit-to-animal gate. Position A argues that peripheral whole-blood potency (17.7 nM) plus mechanistic precedents showing CNS efficacy of NLRP3 NACHT inhibitors, plus non-zero brain penetrance (Kp,uu ~0.22), plus an active field hypothesis that peripheral suppression can confer CNS benefit, meets a 'sufficiency' standard. Position B argues that the inference from peripheral engagement to central efficacy is unverified, the IC50 estimate is fragile (only two of four replicates remain), and that every precedent with demonstrated AD efficacy carries direct central engagement data that this candidate lacks. After weighing both sides, Position B's anchored criticisms carry greater weight on this specific claim. The verified precedents (dapansutrile/OLT1177 in APP/PS1; VEN-02XX in 5XFAD; NT-0796 with CSF biomarker reductions in PD; VENT-02 with human CSF exposure) all demonstrate that NLRP3 NACHT inhibition CAN modify CNS pathology, but ONLY when accompanied by confirmed CNS exposure or direct central pharmacodynamic data. These precedents therefore validate the MECHANISM but do not support the INFERENCE that peripheral whole-blood potency alone signals CNS-relevant target engagement. The Kp,uu ~0.22 is a predicted property, not a verified CNS exposure measurement. The two-replicate IC50, while not ruled invalid, is thin. The field debate over peripheral-to-CNS translation (precedent_p340e7b) is genuinely unresolved; Position A reads it as supportive, Position B reads it as undermining. On the evidence in the record, the safer reading is that this debate is unsettled and therefore cannot bridge the gap. The core principle is that comparability must rest on shared basis, not shared category. Position A's precedents share mechanism and indication with the candidate, but they differ on the critical dimension that determines this claim: verified central compartment engagement. Because the candidate lacks even a microglial secondary assay, the panel does not reach the sufficiency threshold for a CNS indication at this gate.

The claim under review is whether the candidate's target-engagement package is sufficient at the commit-to-animal gate for an Alzheimer's disease program. The target for AD is microglial NLRP3 in the CNS. Position A argues that potent peripheral whole-blood inhibition (IC50 17.7 nM), a calculated Kp,uu of 0.22, and mechanism validation from brain-penetrant precedents make CNS engagement 'inferentially plausible.' Position B argues that without any direct CNS-relevant evidence—no microglial potency, no measured brain PK confirming free concentrations above a CNS-relevant IC50, and no central PD marker—the claim fails. After weighing both sides on anchoring to the record: (1) The candidate's whole-blood IC50 is verified in the record as a peripheral-compartment measure. Peripheral potency, however high, is not direct evidence of CNS target engagement. (2) The Kp,uu of 0.22 is a calculated value with acknowledged P-gp efflux, not a measured PK result; it supports extrapolation but does not verify CNS exposure. (3) The precedents Position A relies on (dapansutrile, MCC950, VEN-02XX, NT-0796, VENT-02, VTX3232, usnoflast) all supply in vivo CNS efficacy, measured brain penetration, or clinical CSF biomarker data that the candidate lacks. Their value is mechanism validation, not evidence that the candidate's specific package meets a sufficiency standard. Position A's comparability rests on shared category (mechanism, indication) rather than a shared basis for sufficiency at this gate. (4) Position B's core disqualifying objection—the absence of any direct CNS engagement evidence—is confirmed by the record. The declared microglial assay was not reported. This is not a preference for more data; it is a gap in the evidence for the disease-relevant compartment. (5) Position B's characterization of precedent_p340e7b as documenting an 'unresolved field debate' is somewhat overstated relative to the retrieved record (PMID:31359456), but this does not weaken the core biological point that peripheral blood inhibition cannot reliably substitute for CNS engagement evidence in AD. The strongest constructive points (high potency, stable replicate, validated mechanism) are real but do not bridge the compartment gap. Therefore, on the evidence in the record, Position B's skepticism is better anchored. The evidence does not establish that the candidate will engage NLRP3 in the CNS at doses projected for efficacy. A single measured microglial IC50 or a rodent brain PK study showing free brain concentration relative to potency would materially change the resolution.

Position B’s skeptical assessment is better anchored to the record. The decisive break is the dapansutrile precedent (precedent_pc7b071): its value as a translational precedent for AD rests on verified central efficacy (cognitive rescue, microglial attenuation, plaque reduction) in addition to shared mechanism. Position A’s potency comparison treats shared mechanism and readout class as sufficient common scale, but B correctly shows the precedent is mismatched on the decisive property—demonstrated central engagement—because the candidate has no microglial assay, no CSF data, and no CNS efficacy. The unresolved peripheral-versus-central debate (precedent_p340e7b) cannot anchor a claim of sufficiency; a contested, unproven hypothesis does not neutralize a confirmed gap. NT-0796 (precedent_peb7226) reinforces that contemporary NLRP3 neurodegeneration programs verify central biomarker engagement, setting an implicit verification standard the candidate has not met. The verified facts—whole-blood IC50 17.7 nM (two replicates after exclusions), Kp,uu 0.22, acknowledged P-gp efflux, and an unreported microglial assay—do not, on the record, bridge peripheral potency to central pharmacology. The open disqualifying objection (missing CNS-relevant engagement data) is confirmed by the record and is not neutralized by A’s extrapolations or by precedents that all include central evidence.

Position B prevails because it anchors its objection to a specific, record-confirmed gap: the hepatic-transporter liability is described only qualitatively ('modest activity at one hepatic transporter') with no transporter identity, IC50, percent inhibition, or therapeutic margin against the NLRP3 IC50 of 17.9 nM. Under the principle of anchoring over force, this unquantified liability is not neutralized by Position A's strong selectivity data elsewhere; an open disqualifying objection on hepatic safety, confirmed by the record as unresolved, stands on its own. Position A's comparison to dapansutrile (precedent_pc7b071) fails under the shared-basis principle because the precedent's safety profile is positively established ('safe in humans,' PMID:33257576) whereas the candidate's hepatic liability lacks quantitative verification. Position A treats a reported qualitative descriptor ('modest') as if it were a verified safety margin, violating the principle to separate verified from reported. The specific MCC950 hepatotoxicity threshold invoked by Position A (~1200 mg/day, >100 uM Cmax) is not visible in the retrieved abstracts (PMID:30381407), further weakening its anchoring. While the selectivity discrimination over AIM2, NLRC4, and NLRP1 is excellent and undisputed, that verified strength does not overcome the confirmed gap in hepatic characterization at the commit-to-animal gate.

The claim asks whether the selectivity panel readout is sufficient at the commit-to-animal gate. Position A correctly notes that the NLR-family target selectivity is quantitatively strong (>558-fold window). However, sufficiency is a gate-level judgment about the readout as a whole. The record itself, as described by both positions, contains a selectivity-panel footnote that flags hepatic-transporter inhibition and instructs that it must be weighed alongside a hepatic-safety readout. Position B demonstrates that this hepatic-safety readout is absent from the record. A readout that internally directs the decision-maker to consult missing evidence cannot, on its own terms, be deemed sufficient. Position A's reliance on class precedents (Dapansutrile and MCC950) to characterize the liability as manageable is not anchored to candidate-specific hepatic-safety data; the precedents are therefore not on a common scale for safety comparison. Because the record acknowledges the need for hepatic-safety data and that data is missing, the strongest objection is record-level and disqualifying for the sufficiency claim. What would change the answer: inclusion of a hepatic-safety readout (e.g., in vitro hepatotoxicity assay, repeat-dose rodent ALT/histology, or quantitative transporter IC50 with safety margin) showing the transporter signal is either artifactual or has a clear safety margin.

The claim of selectivity_sufficiency requires evidence adequate to judge whether off-target liabilities are manageable at the commit-to-animal gate. Position A anchors the on-target NLR selectivity (IC50 17.9 nM vs >10,000 nM) but extends its sufficiency argument by treating a qualitative record descriptor ('modest' hepatic-transporter activity) as quantitatively adjudicated. Position B identifies a material gap: the record provides no IC50, transporter identity, or margin-of-safety for this liability, and the hepatic-safety readout needed to weigh it is absent. Under the principle that a disqualifying objection must be given its proper weight, this gap is decisive because the precedent MCC950 establishes that hepatic liabilities can override efficacy in this mechanistic class, and the positive precedent Dapansutrile carries no reported hepatic-transporter inhibition to justify tolerating an uncharacterized signal. Because the claim explicitly requires weighing the hepatic liability and the record lacks the quantitative data to do so, the sufficiency assertion rests on an unverified assumption. The answer would change with quantitative hepatic-transporter data and an integrated hepatic-safety readout demonstrating an acceptable margin.

The claim that the selectivity panel is sufficient to support advancement rests on two pillars in Position A: (1) robust >500-fold selectivity over related inflammasome sensors, which is well-anchored in the record (IC50 17.9 nM vs >10,000 nM), and (2) the assertion that an associated hepatic-transporter liability is 'modest' and outweighed by an uncharacterized hepatic-safety readout. Position B demonstrates that the second pillar is unanchored: the hepatic-transporter liability lacks numeric value, transporter identity, or functional assay in the record, and no hepatic-safety readout for the candidate is in evidence. At a commit-to-animal gate, an unquantified hepatic signal in a mechanism class with a documented hepatotoxicity failure (MCC950, precedent_p7bbc38) cannot be dismissed as 'subtle' without record support. The class precedent Dapansutrile (precedent_pc7b071) advanced on an explicitly favorable hepatic-safety profile, establishing that the bar for this mechanism class includes demonstrated hepatic safety. Position A's additional precedents (VENT-02, NT-0796, VTX3232, VEN-02XX) are presented as evidence that progression is compatible with hepatic flags, but the record does not show those candidates carried an unquantified hepatic-transporter signal, so their progression does not lower the threshold for the candidate. Because the positive claim of sufficiency requires anchored evidence for all material liabilities, and the hepatic-transporter liability is unquantified while hepatic-safety data are absent, the claim is not supported on the current record. The strongest open objection is the absence of candidate-specific hepatic-safety data; if obtained and favorable, it would materially weaken Position B's case.

The claim of selectivity_sufficiency is anchored to a quantitative selectivity panel demonstrating a >500-fold window for NLRP3 over related NLRs (IC50 17.9 nM vs >10,000 nM), which satisfies the standard of sufficiency for a commit-to-animal gate. The skeptical objection correctly identifies a gap—no quantitative hepatic-transporter activity value and no hepatic-safety readout in the record—but this gap pertains to a distinct ADMET liability, not to the selectivity readout itself. The constructive position appropriately contextualizes the modest transporter signal against class precedents (dapansutrile advancing with low hepatotoxicity; MCC950 halted by severe hepatotoxicity), showing that hepatic liabilities in this class exist on a spectrum. At the pre-animal gate, the standard is sufficiency to proceed with managed risk, not completion of clinical safety validation. The record supports the characterization of the hepatic liability as modest and flagged for monitoring; without evidence that this qualitative signal falls on the severe end of the class spectrum, the open gap does not override the well-anchored selectivity data. Therefore, the evidence favors A, conditioned on obtaining hepatic-margin data before later gates.

The claim fails because Position A's core precedent (dapansutrile/APP/PS1, precedent_pc7b071) cannot bear the weight placed on it. The primary record (PMID:33257576) reports no quantitative brain penetrance metrics for dapansutrile—no Kp,uu, brain:plasma ratio, or unbound fraction—so there is no common exposure/penetrance basis on which to compare the candidate's measured Kp,uu 0.22. Position A asserts dapansutrile achieved 'brain penetration at higher doses,' but this is not anchored in the primary scientific record; the PNAS paper does not report brain PK. The efficacy in that study was achieved via dietary chow at 7.5 g/kg feed, an extraordinarily high exposure paradigm that does not translate to conventional dosing and provides no basis to infer that borderline penetrance (Kp,uu ~0.22) would be sufficient. Additionally, the peripheral-vs-central NLRP3 mechanism debate remains unresolved (Tejera et al. 2019, DOI:10.15252/embj.2018101064), meaning dapansutrile's APP/PS1 rescue may have occurred via systemic rather than central NLRP3 inhibition, further breaking the comparison on the property the claim hinges on. The supplementary precedents (VEN-02XX in 5XFAD, VENT-02 FIH, NT-0796) support the broader class principle that brain-penetrant NLRP3 inhibitors can achieve CNS target engagement and AD-model efficacy, but they do not address whether the candidate's specific penetrance profile—Kp,uu 0.22 with P-gp efflux ratio 4.8—is sufficient for the claimed outcome. Position B has identified a record-supported disqualifying flaw in Position A's central comparison.

The claim asserts that the candidate's measured CNS penetrance (Kp,uu 0.22, P-gp ER 4.8) is sufficient to support commit-to-animal, anchored to a dapansutrile precedent that achieved APP/PS1 cognitive rescue. Position B's disqualifying objection is record-anchored and decisive: the primary precedent publication (PMID:33257576) contains no quantified brain exposure data—no Kp,uu, Kp,brain, unbound fractions, or brain:plasma ratios. Both positions acknowledge the precedent's brain penetration is attributed ('reported_not_verified') rather than measured in the cited primary source. Because the precedent lacks the very pharmacokinetic measurement on which the comparability depends, it cannot establish a sufficiency threshold for CNS exposure. Position A's 'plausibly within range' argument is therefore an extrapolation from an unverified attribute, not an anchored comparison. The field-level peripheral-vs-central debate (precedent_p340e7b, supported by DOI:10.15252/embj.2018101064) is unresolved; while it raises an alternative rationale for proceeding (peripheral NLRP3 suppression may suffice), this does not support the specific claim that CNS penetrance is sufficient—it merely suggests the candidate might advance on different mechanistic grounds. The material P-gp efflux liability (ER 4.8) remains an unmitigated risk that the precedent cannot address due to its missing PK bridge. Evidence that would change the resolution includes: (1) quantified brain PK for dapansutrile in the APP/PS1 model establishing a Kp,uu benchmark, or (2) a demonstration that peripheral-restricted NLRP3 inhibition rescues APP/PS1 cognition without central exposure.

The claim under arbitration is specifically 'cns_penetrance_sufficiency'—whether the candidate's measured CNS exposure (Kp,uu ~0.22, P-gp ER ~4.8) is sufficient to support advancing to in-vivo AD-efficacy studies. Position A anchored its case in three precedents. The primary precedent, dapansutrile/OLT1177 in APP/PS1 (PMID:33257576), validates NLRP3 NACHT-domain inhibition in the identical AD model but reports no quantitative brain exposure metrics—no Kp,uu, brain:plasma ratio, or P-gp efflux data. This confirms Position B's disqualifying objection: the precedent cannot serve as a scale to judge whether 0.22 is 'sufficient' because it provides no benchmark exposure value. Position A's second precedent, VEN-02XX (DOI:10.1038/s44400-025-00011-5), is brain-penetrant and rescues cognition in an AD model, but it uses the 5XFAD/Rubicon KO model rather than APP/PS1 and reports no Kp,uu value for cross-calibration. Position A's third precedent, MCC950 (PMID:30381407), is misanchored: the cited record describes Parkinson's disease models (alpha-synuclein propagation), not APP/PS1 Alzheimer's, and contains no BBB-crossing data. Because the specific claim hinges on penetrance sufficiency, mechanism validation alone cannot compensate for the missing quantitative CNS exposure scale. The candidate's measured Kp,uu of 0.22 is real data and counts in its favor, but without a precedent demonstrating efficacy at or below this exposure level—or any exposure level—in a comparable model, the sufficiency claim is unsupported by the record. The P-gp efflux ratio of ~4.8 remains an open liability that further complicates dose-exposure predictions. The strongest constructive element (mechanism validation in APP/PS1) and the strongest objection (broken quantitative CNS exposure comparison) are kept distinct; the latter breaks the specific claim.

Position A argues the claim holds by assembling multiple precedents showing NLRP3 NACHT inhibition rescues cognition, reduces pathology, and modulates biomarkers in APP/PS1 and related models, treating the NfL trend as directionally consistent and within a predefined trend band. Position B argues the claim does not hold because two disqualifying objections remain open: the NfL readout is non-significant (p=0.099), falling below conventional alpha, and model-choice ambiguity is unresolved because no 5xFAD data exist for the candidate while a comparable compound demonstrated efficacy there. Adjudicating neutrally: (1) The precedents for APP/PS1 efficacy (Dapansutrile, JC124, MCC950 genetic/pharmacological protection) are well-anchored in the record and establish a robust mechanistic rationale. Position A correctly notes that NLRP3 inhibition in APP/PS1 is densely precedented. (2) The cross-model point is more complex: Position A uses VEN-02XX in 5xFAD as evidence that the mechanism generalizes across models, but this does not resolve whether the *candidate* would replicate in 5xFAD. Position B correctly identifies that the candidate itself lacks 5xFAD data; the generalizability argument is extrapolation, not candidate-specific confirmation. (3) The NfL biomarker is the decisive fracture point. Position B anchors its objection to a conventional statistical threshold (p<0.05) and notes that peer programs treat NfL as load-bearing. Position A counters that the trend is within a predefined band and aligns with clinical precedent (NT-0796). However, the retrieved abstract for PMID:40792655 (NT-0796 in PD) does not mention NfL at all in the visible record; it reports IL-1β, IL-6, IL-18, CRP, and fibrinogen. This undermines Position A's anchoring for clinical NfL precedent from this citation. Without a verified record item showing NT-0796 reduced CSF NfL, Position A's NfL argument rests partly on an asserted claim not clearly supported by the retrieved text. Conversely, Position B's assertion that peer programs require significant NfL reduction is stated as a field convention but is not itself anchored to a retrieved record item specifying this threshold. Both sides have partially unanchored claims on the NfL point. (4) The cytokine biomarkers (IL-1β, IL-18) are significantly decreased, confirming target engagement. This is undisputed and well-anchored. The question is whether target-engagement biomarkers alone, with a non-significant neuronal-protection biomarker trend, suffice at the commit-to-animal gate. Position A says yes, given the model precedent; Position B says no, because neuronal protection requires direct evidence. Neither side fully resolves this because the gate definition itself is not in the record. (5) The disqualifying objections are open, not ruled out. The record does not confirm that a p=0.099 trend is sufficient, nor does it confirm that APP/PS1-only data generalizes. The strongest constructive evidence is the APP/PS1 replication pattern; the strongest objection is the unverified NfL anchoring and the unresolved model-choice gap. Because a disqualifying objection remains open and the constructive case relies partly on an unverified NfL precedent claim, the evidence does not clearly satisfy the claim, yet the constructive evidence is substantial enough that a 'no' verdict would also overreach. The proper resolution is unresolved, with the specific conditions for resolution stated.

At the commit-to-animal gate, the claim is sufficiently supported by multi-modal pharmacodynamic signals in APP/PS1 (partial cognition rescue, reduced microglial activation, decreased brain IL-1β/IL-18, modest plaque reduction) that are directly matched to established class precedents (Dapansutrile PMID:33257576; JC124 PMID:34219728) in the same model. The brain cytokine reductions function as verified central target-engagement markers, mitigating concern about borderline Kp,uu. Position B raises three compounding fragilities, but only two survive anchoring scrutiny: (1) the plasma NfL p=0.099 is a genuine negative point, yet at the sufficiency standard it is not disqualifying when direct PD markers confirm engagement; (2) the lack of cross-model validation is a real gap but does not negate the APP/PS1 signal, which replicates the model in which the class precedent demonstrated efficacy. Position B's third pillar—the 'unresolved central-vs-peripheral debate' anchored to ISRCTN:85338453 and precedent_p340e7b—is unanchored; ISRCTN:85338453 returned no relevant trial record, and the EMBO paper (PMID:31359456) only confirms peripheral NLRP3 contributes to AD pathology, not that peripheral suppression suffices. The verified-versus-reported split: verified in the record are the Dapansutrile complete cognitive rescue, JC124 APP/PS1 efficacy, and VEN-02XX 5XFAD/Rubicon KO rescue; reported but not independently retrieved are the candidate's specific brain IL-1β/IL-18 and Kp,uu values, which both positions treat as in the firewalled evidence record. The strongest open objection is the non-significant plasma NfL, which would become resolved with a statistically significant NfL reduction or a CSF target-engagement biomarker (e.g., CSF IL-1β). What would change the answer: definitive evidence that the brain cytokine reductions are peripheral artifacts rather than central target engagement, or a cross-model failure in 5XFAD or another AD background.

Position A’s constructive case is better anchored to verified record items. The Dapansutrile (PMID:33257576) and JC124 (PMID:34219728) precedents share the APP/PS1 model, NLRP3 mechanism, and readout class (cognition, microglial activation, amyloid burden, brain cytokines), establishing that the candidate’s partial signal profile is mechanistically plausible and not model-unique. The VEN-02XX precedent (DOI:10.1038/s44400-025-00011-5) in 5xFAD mitigates model-specificity concerns at the class level, even though it does not replace candidate-specific confirmatory data. Position B’s central-vs-peripheral disqualification is the strongest objection, but it is materially weakened by the candidate’s own CNS biomarker changes (brain IL-1β/IL-18 reduction, Iba1 reduction), which are inconsistent with a purely peripheral mechanism and provide direct, if modest, evidence of central target engagement despite borderline Kp,uu. Position B’s NfL objection rests on NT-0796 NfL data that are asserted but not verified in the retrieved record (PMID:40792655/37874905 abstracts contain no NfL mention); under the anchoring principle, this cannot carry disqualifying weight at the commit-to-animal gate. Similarly, the TIER_1/TIER_1 penetration attribution claimed for Dapansutrile is not visible in the retrieved record, so Position B’s claim of superior precedent penetration is unanchored. The modest magnitude of the candidate’s efficacy signals is acknowledged, but at this gate the primary readouts are coherent, precedent-supported, and accompanied by CNS biomarker evidence that overrides the peripheral-ambiguity objection.

Position A better anchors its constructive case to verified record items: significant brain cytokine reductions (IL-1β, IL-18), partial cognitive rescue, and modest plaque reduction in the validated APP/PS1 model, plus a plasma NfL trend (p=0.099) that A contextualizes within a predefined [0.05,0.1] trend band. While Position B correctly identifies an open objection—that p=0.099 does not meet conventional α=0.05 significance—B does not refute A's claim that the trend band was predefined, and the NfL is one of several biomarkers rather than a standalone gatekeeper. B's model-generalization concern (APP/PS1 vs 5xFAD) is speculative without record evidence that APP/PS1 is permissive for NLRP3 inhibitors in a way that invalidates the signal; at a commit-to-animal gate, single-model efficacy in an accepted amyloid model is standardly sufficient to advance. B's peripheral-vs-central concern is partially mitigated by the observed brain cytokine reductions. The precedents pc7b071 and p7bbc38 provide direct mechanism-and-model comparability that support continuation, despite modest effect size. The package as a whole meets the threshold for committing to further in-vivo studies, provided the NfL trend and model specificity are addressed in downstream design.

The record anchors constructive support in a validated APP/PS1 dataset showing partial cognitive rescue, significant brain and plasma cytokine reductions, and modest plaque decrease, which aligns with precedents for direct NLRP3 NACHT inhibition in the same model (precedent_pc7b071, precedent_p17d8f1). However, per the principle that an open disqualifying objection is not neutralized by a strong constructive case elsewhere, the skeptical objections remain open: the plasma NfL reduction is a non-significant trend (p = 0.099), and the candidate has not been tested in an independent AD model such as 5xFAD, leaving model-generality unresolved. The claim of sufficiency depends on an undefined threshold—whether a single-model partial rescue with significant upstream pharmacodynamics but a non-significant downstream neurodegeneration biomarker is enough to commit to further in-vivo AD-efficacy studies—and the record does not resolve that threshold. Because the evidence supports both the presence of a coherent efficacy signal and the presence of material gaps, the claim is genuinely unresolved.

The evidence moderately supports Position A. The candidate's hepatic signal is anchored as mild, dose-dependent, and reversible upon washout. This reversibility is a genuine differentiator from MCC950's unexplained clinical transaminase elevations that halted Phase 2 development. The precedent of dapansutrile demonstrates that the NLRP3 NACHT ATPase mechanistic class is not uniformly hepatotoxic and is clinically viable. At the commit-to-animal gate, the governing criterion is whether efficacy can be tested in a relevant animal model with an adequate safety framework; a reversible hepatic signal provides a clear dose ceiling and monitoring framework rather than a hard stop. Position B's argument that the exact signal was a development-halting liability is weakened by evidence that MCC950's hepatotoxicity was likely attributable to off-target carbonic anhydrase inhibition rather than the NLRP3 mechanism itself, and by the qualitative gulf between reversible preclinical signals and unexplained clinical toxicity. Position B correctly identifies the strongest open objection: the record contains no structural evidence excluding the candidate from sharing MCC950's off-target liability, and no therapeutic-window analysis demonstrating that projected efficacious exposures remain safely below the hepatic-signal threshold. These gaps are genuine but do not overturn the constructive case at this gate, because they are addressable during animal efficacy studies and do not render the current signal profile unmanageable. Evidence that would change the answer: (1) structural data showing the candidate shares MCC950's furan ring or carbonic anhydrase liability, or (2) a therapeutic-window analysis showing the efficacious dose encroaches on the hepatic-signal range, or (3) evidence that the candidate's transaminase elevation is not reversible or is accompanied by histopathologic injury.

Position B identifies a specific, record-anchored gap that Position A does not close: there is no evidence in the record that the candidate's hepatic signal has been structurally or mechanistically decoupled from the MCC950 class-killing liability. Position A correctly notes that dapansutrile demonstrates the NLRP3 NACHT-inhibitor class can advance with low hepatotoxicity, and that MCC950's liability may be molecule-specific. However, A does not provide record evidence showing the candidate resembles the safe precedent (dapansutrile) rather than the failed one (MCC950) on the structural dimension that drives hepatotoxicity. At a commit-to-animal gate, the burden rests on the constructive position to show that a signal explicitly described as 'mirroring' a halted-program liability is nevertheless safe to advance. 'Mild and reversible' preclinical transaminase elevation at high dose was precisely MCC950's preclinical profile before it failed in Phase 2. Without structural or mechanistic decoupling evidence, the candidate's position on the wrong side of the class split remains the stronger inference from the record. The strongest open objection is therefore confirmed as unresolved, not ruled out.

Position B identifies a specific, unaddressed disqualifying gap: no therapeutic margin is demonstrated between the systemic exposure required for CNS efficacy and the exposure at which mild reversible transaminase elevation occurs. Position A asserts that PK parameters (F = 41.9%, t½ = 6.5 h) support dose selection below the hepatic threshold, but this assertion does not account for the record data that CNS penetration is borderline (Kp,uu ~0.22 with P-gp efflux). Because efficacious CNS exposure may require higher systemic doses, the optimistic PK interpretation is incomplete. The dapansutrile precedent (precedent_pc7b071) shows that low hepatotoxicity is achievable in the NLRP3 inhibitor class, but this does not support the candidate's specific liability being manageable; rather, it suggests the candidate's signal may be chemical-series-specific. The MCC950 precedent (precedent_p7bbc38) is cited as a class caution, but its clinical discontinuation is not verified in the retrieved primary record. On the evidence actually in the record, the candidate's hepatic signal is mild and reversible, yet the absence of a bridged therapeutic margin leaves the 'manageable' conclusion unsupported at this gate.

Position A's core argument is anchored in standard toxicological interpretation: a hepatic signal that is mild, dose-dependent, and reversible on washout indicates an exposure-driven effect amenable to management through dose-ranging, exposure monitoring, and washout protocols. These characteristics differentiate it materially from MCC950's severe, clinically disqualifying DILI, which occurred at supratherapeutic human exposures (1200 mg/day) and was not reversible in the same sense. At a commit-to-animal gate, the standard is not clinical approval but sufficient safety to justify in-vivo efficacy studies with safeguards; a reversible, dose-dependent signal meets that standard. Dapansutrile provides valid precedent that NLRP3 NACHT-domain inhibition is not intrinsically hepatotoxic, supporting the inference that the candidate's signal is compound-specific rather than mechanism-mandated. Position B's strongest objection—the borderline brain penetration implying higher systemic doses may encroach on the hepatotoxic range—is speculative and not confirmed by the record; it remains an open risk that should be addressed in study design but does not, on the current record, rebut the manageability of the observed signal. Position A's furan-ring structural attribution is unverified and should be disregarded, but it is not load-bearing for A's conclusion. Position B overstates the 'mirroring' claim: the record describes different severity and reversibility profiles.

The claim that hepatic sufficiency is established at the commit-to-animal gate is not supported on the record. Position A's constructive case rests on two comparability arguments, both of which fail anchoring tests. First, precedent_pc7b071 (dapansutrile): the cited PMID:33257576 is a preclinical mouse efficacy study that does not contain hepatic safety data for dapansutrile. Position A infers that because dapansutrile (same mechanism) is safe, the mechanism itself is not hepatotoxic; however, this ignores the possibility of compound-specific (off-mechanism) toxicity and the fact that the candidate exhibits a signal dapansutrile avoided. The dapansutrile Phase 1B trial (PMID:33235030, not cited) reports short-term tolerability but does not characterize hepatotoxicity risk or contrast with MCC950. Therefore, dapansutrile does not count toward the candidate's claim. Second, precedent_p7bbc38 (MCC950): Position A uses MCC950 as a severity comparator, arguing the candidate's profile is milder and reversible. Position B correctly notes that this does not resolve the core issue. The record does not contain evidence that the candidate's hepatic signal is mechanistically differentiated from MCC950's. Position A's assertion that MCC950's toxicity was due to a 'furan-ring' toxicophore is unverified by any citation; this is reported background knowledge, not record evidence. Without mechanistic differentiation, the candidate's signal remains an open disqualifying objection that echoes a class caution severe enough to halt a prior program. At the commit-to-animal gate, a signal mirroring a program-ending class toxicity must be de-risked—through structural differentiation, reactive-metabolite data, or demonstrated therapeutic index—before efficacy studies are justified. The record contains none of this. Reversibility in rodents and dose-dependency alone do not establish clinical safety margin. The strongest open objection (absence of mechanistic differentiation from MCC950) is confirmed by the empty search for furan-ring attribution and remains unclosed. Therefore, the claim does not hold.

The claim under arbitration is developability_sufficiency at the commit-to-animal gate. Position A argues that precedent NLRP3 inhibitors overcame CNS-penetration limitations through dose/formulation optimization, so the candidate's borderline CNS profile is an acceptable risk. Position B argues the claim fails because the candidate has no verified path to reproducible CNS exposure: the enabling amorphous dispersion is unmanufactured and metastable, and even if perfected, P-gp efflux and borderline CNS-MPO may still prevent sufficient free brain concentration. The crux is whether precedents show the candidate can overcome its specific liabilities. For precedent_pc7b071 (dapansutrile/OLT1177), Position A states dapansutrile was originally peripheral and achieved brain penetration at higher doses. Position B correctly rebuts that dapansutrile's brain penetration was established preclinically, whereas the candidate's is only prospective. On the stated common_scale_basis (matched mechanism, matched AD model readout), the two positions diverge on counts_toward_claim: A says with_caveat, B says no. B's objection is anchored and specific: the precedent had verified CNS exposure; the candidate does not. The other three precedents (VEN-02XX, VENT-02, NT-0796) are not engaged by Position B at all, but A's VENT-02 citation (PMC:13132802) retrieved an unrelated paper, making that precedent's anchoring unverified. VEN-02XX and NT-0796 are verified as brain-penetrant NLRP3 inhibitors, but neither addresses the candidate's specific formulation gap or its P-gp/CNS-MPO liabilities. The principle of anchoring governs: a point counts only to the extent it is tied to a specific record item. The candidate's specific gap—no manufactured, characterized amorphous dispersion and no demonstrated CNS exposure—is a record item that Position A does not rebut with a matching verified item. The principle of giving the disqualifying objection its proper weight applies: an open disqualifying objection is not neutralized by a strong constructive case elsewhere. The unresolved formulation gap is disqualifying at the commit-to-animal gate because it prevents an interpretable efficacy study. Therefore, on the evidence in the record, the claim fails.

Position A constructs a strong, anchored case for NLRP3 mechanism validation in AD and class-wide achievability of CNS exposure. However, per the principle of resolving support to its stated basis, the precedents A invokes demonstrate that CNS-penetrant NLRP3 inhibitors are achievable as a class but do not establish that this candidate's specific developability package is sufficient. Dapansutrile had reported preclinical CNS penetration at higher doses as an exposure basis for its APP/PS1 efficacy; the candidate lacks any analogous exposure basis and its developability is explicitly characterized in the record as unresolved at this gate. VENT-02, NT-0796, and VTX3232 are more advanced compounds with demonstrated human or preclinical CSF exposure, illustrating the evidentiary standard for CNS developability rather than supporting the candidate's sufficiency. Per the principle of giving disqualifying objections proper weight, Position B's anchored objection stands: an unmanufactured metastable amorphous dispersion coupled with confirmed P-gp efflux and borderline CNS-MPO does not provide a verified, reproducible path to brain exposure. At a commit-to-animal gate, this gap makes the efficacy study pharmacologically uninterpretable because pharmaceutical failure cannot be distinguished from target failure. The claim therefore fails on the evidence.

Position B wins on anchoring because it correctly identified a categorical developability mismatch that is verified in the record: Dapansutrile (PubChem CID 12714644) is a tiny, highly soluble molecule (MW 133.17, xlogp -0.7, TPSA 66.3) with no formulation dependency, whereas the candidate requires an unmade, metastable amorphous dispersion whose stability is uncharacterized. Position A acknowledged this exact difference in its comparability table but still marked Dapansutrile as 'counts_toward_claim: yes' on the basis of matched mechanism and AD model, not matched developability. Under the principle that support resolves only to its stated basis, a precedent matched on mechanism and model cannot carry developability credit when the developability profiles are categorically different and the precedent's success was achieved under conditions the candidate cannot replicate without first solving an unmet formulation challenge. Position A's additional clinical-stage precedents (VENT-02, NT-0796, VTX3232) demonstrate that CNS-penetrant oral NLRP3 inhibitors are achievable in the class, but they are aspirational benchmarks, not evidence that this candidate's borderline CNS-MPO score, P-gp efflux liability, and unverified Kp,uu ~0.22 are sufficient. The unmade amorphous dispersion remains an open disqualifying objection: the record neither rules it out nor confirms the candidate can achieve reproducible exposure through it. Position A's argument that the gate purpose is to test mechanism, not deliver final formulation, is a defensible procedural framing but does not neutralize the specific, anchored gap in the candidate's developability evidence. The strongest open question is whether a standard amorphous dispersion would actually deliver adequate and reproducible CNS exposure for this specific molecule; the record contains no evidence that it would.

At a commit-to-animal gate, developability sufficiency requires a reproducible path to exposure that bridges efficacy and toxicology. The record confirms the candidate's CNS exposure depends on an unmade, metastable amorphous dispersion with acknowledged recrystallization risk. Position A cites strong class precedent that NLRP3 inhibitors achieve CNS exposure and AD-model efficacy, but every precedent relied on a demonstrated, established formulation—not a hypothetical, unmade dispersion. Position B correctly identifies that this breaks the comparability basis for developability: the common scale is mechanism and readout class, not the enabling formulation. Because the candidate's specific developability profile is gated by an unverified technical dependency, and class precedent does not validate this specific gap, the claim of developability sufficiency at this gate is not supported on the record. The evidence that would change the answer is: (1) manufacture and characterization of the amorphous dispersion with stability data showing controlled release and reproducible exposure, and (2) PK data demonstrating that the dispersion achieves supra-IC90 CNS exposure in a relevant species.

The evidence in the record does not support the claim that the candidate's developability profile is sufficient to advance to in-vivo AD-efficacy studies. Position B anchored a specific, record-confirmed disqualifying gap: the enabling amorphous dispersion has not been manufactured, and the record explicitly warns that amorphous forms are metastable and can recrystallize. This creates a bridgeability risk between efficacy-study exposure and toxicology-study exposure that undermines the interpretability of any efficacy data. All precedents cited by both positions—dapansutrile, VENT-02, NT-0796, usnoflast, and VEN-02XX—had demonstrated or reported CNS exposure, establishing a verified-exposure threshold the candidate has not met. Position A's class-level validation argument is record-anchored (brain-penetrant NLRP3 inhibitors are pharmacologically and clinically achievable), but class validation does not bridge a candidate-specific formulation gap. The candidate's Kp,uu ~0.22, high passive permeability, and borderline CNS-MPO-like score are predicted or developability-stage parameters, not verified in-vivo exposure. Position A's proposal to address residual uncertainties 'in parallel with the efficacy package' does not rebut the bridgeability concern; it defers a precondition that the record shows is currently unfulfilled. The strongest open objection—unmade enabling formulation with metastability-driven reproducibility risk—remains confirmed by the record and unaddressed by the constructive case.